In vitro biotransformation of a novel antimalarial cysteine protease inhibitor in human liver microsomes

Pharmacology

Volumn 58, Issue 3, 1999, Pages 147-159

  Zhang, Yuanchao ^a   Guo, Xisheng ^a   Lin, Emil T ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

, unsaturated ketone; Cysteine protease inhibitor; Cytochrome P450 3A; Malaria; NADPH cytochrome P450 reductase; P glycoprotein

Indexed keywords

ANTIBODY; ANTIMALARIAL AGENT; CARBON MONOXIDE; COMPLEMENTARY DNA; CYSTEINE PROTEINASE INHIBITOR; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; KETOCONAZOLE; POLYCLONAL ANTIBODY; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE;

ARTICLE; CONTROLLED STUDY; DRUG TRANSFORMATION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTIMALARIALS; ARYL HYDROCARBON HYDROXYLASES; AUTORADIOGRAPHY; BIOTRANSFORMATION; CELL LINE; CHALCONES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTEINE PROTEINASE INHIBITORS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; IMIDAZOLES; MASS SPECTROMETRY; MICROSOMES, LIVER; MIDAZOLAM; MIXED FUNCTION OXYGENASES; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; PHOTOAFFINITY LABELS; RABBITS; RATS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0032932909     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028277     Document Type: Article

References (30)

1. Gibbons A: Researchers fret over neglect of 600 million patients. Science 1992;256:1135.
2. World Health Organization Malaria Action Program: Severe and complicated malaria. Trans R Trop Med Hyg 1986;80:1-50.
3. Li R, Chen X, Gong B, Dominguez JN, Davidson E, Kurzban G, Miller RE, Nuzum EO, Rosenthal PJ, McKerrow JH, Kenyon GL, Cohen FE: In vitro antimalarial activity of chalcones and their derivatives. J Med Chem 1995;38:5031-5037.
4. Benet LZ, Kroetz DL, Sheiner LB: Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination; in Hardman JH, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds): Goodman & Gilman's The Pharmacological Basis of Therapeutics, ed 9. New York, McGraw-Hill, 1996, chapt 1, pp 3-28.
5. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ: Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-457.
6. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ: Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-497.
7. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
8. Sevrioukova IF, Peterson JA: NADPH-P450 reductase: Structural and functional comparisons of the eukaryotic and prokaryotic isoforms. Biochimie 1995;77:562-572.
9. Cretton EM, Sommadossi JP: Reduction of 3′-azido-2′,3′-dideoxynucleosides to their 3′-amino metabolite is mediated by cytochrome P-450 and NADPH-cytochrome P-450 reductase in rat liver microsomes. Drug Metab Dispos 1993;21: 946-950.
10. Fitzsimmons SA, Lewis AD, Riley RJ, Workman P: Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide(tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: A direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis 1994;15:1503-1510.
11. Surh YJ, Lee SS: Enzymatic reduction of xenobiotic alpha, beta-unsaturated ketone: Formation of allyl alcohol metabolites from shogaol and dehydroparadol. Res Commun Chem Pathol Pharmacol 1994;84: 53-61.
12. Ullman B: Multidrug resistance and P-glycoproteins in parasitic protozoa. J Bioenerg Biomembr 1995;27: 77-84.
13. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
14. Cowman AF, Karcz SR: The pfmdr gene homologues of Plasmodium falciparum. Acta Leidensia 1991;60: 121-129.
15. Cowman AF, Karcz S, Galatis D, Culvenor JG: A P-glycoprotein homologue of Plasmodium falciparum is localized on the digestive vacuole. J Cell Biol 1991;113:1033-1042.
16. Cowman AF, Galatis D, Thompson JK: Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci USA 1994;91:1143-1147.
17. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84:7735-7738.
18. Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJ, Borst P: Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995;31A:1295-1298.
19. Bornheim LM, Correia MA: Effect of cannabidiol on cytochrome P-450 isozymes. Biochem Pharmacol 1989;38:2789-2794.
20. Omura T, Sato R: The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 1964;239:2370-2378.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
22. Wrighton SA, Ring BJ: Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 1994;11:921-924.
23. Beck WT, Cirtain MC, Look AT, Ashmun RA: Reversal of vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil. Cancer Res 1986;46: 778-784.
24. Qian XD, Beck WT: Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistance human leukemic cell lines. Cancer Res 1990;50:1132-1137.
25. Halpert JR, Guengerich FP, Bend JR, Correia MA: Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 1994;125:163-175.
26. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL: Use of midazolam as a human cytochrome P450 3A probe. I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-556.
27. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL: Use of midazolam as a human cytochrome P450 3A probe. II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271:557-566.
28. Tew DG: Inhibition of cytochrome P450 reductase by the diphenyliodonium cation. Kinetic analysis and covalent modifications. Biochemistry 1993;32:10209-10215.
29. Martiney JA, Cerami A, Slater AF: Verapamil reversal of chloroquine resistance in the malaria parasite Plasmodium falciparum is specific for resistant parasites and independent of the weak base effect. J Biol Chem 1995;270:22393-22398.
30. Benet LZ, Wu CY, Hebert MF, Wacher VJ: Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J Controlled Release 1996; 39:139-143.